Cisplatin versus carboplatin in NSCLC: is there one "best" answer?

@article{Sanborn2008CisplatinVC,
  title={Cisplatin versus carboplatin in NSCLC: is there one "best" answer?},
  author={Rachel E Sanborn},
  journal={Current treatment options in oncology},
  year={2008},
  volume={9 4-6},
  pages={326-42}
}
Platinum-based chemotherapeutic doublets have produced significant survival benefits for patients with non-small cell lung cancer of all disease stages. The optimal combination of chemotherapy has been the subject of much investigation, and the ideal platinum agent the subject of ongoing and heated debate. For patients with resected disease, all evidence of survival advantage rests with cisplatin, and the only clinical trial to evaluate carboplatin-based therapy failed to show a survival… CONTINUE READING
Highly Cited
This paper has 22 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…